Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	OLIENA Language recovery after stroke App | Video | PDF (278 pp) | Web

Tuberculosis

Free Subscription 16.07.2018 1 AIDS 2 Antimicrob Agents Chemother 1 Clin Infect Dis 21 Int J Tuberc Lung Dis 1 J Antimicrob Chemother 2 J Clin Microbiol 1 J Infect Dis 2 Lancet Infect Dis 4 Lancet Respir Med 1 N Engl J Med 1 PLoS Med 3 PLoS One

Retrieve available abstracts of this week’s articles: HTML format Text format

Single Articles

AIDS

1. WORODRIA W, Ssempijja V, Hanrahan C, Ssegonja R, et al
   Opportunistic diseases diminish the clinical benefit of immediate antiretroviral therapy in HIV-tuberculosis co-infected adults with low CD4+ counts.
   AIDS. 2018 Jul 12. doi: 10.1097/QAD.0000000000001941.
   PubMed     Text format     Abstract available
   
   

   
   Antimicrob Agents Chemother

2. AGUILAR-PEREZ C, Gracia B, Rodrigues L, Vitoria A, et al
   Synergy between circular bacteriocin AS-48 and ethambutol against Mycobacterium tuberculosis.
   Antimicrob Agents Chemother. 2018 Jul 9. pii: AAC.00359.
   PubMed     Text format     Abstract available
   
   
3. PIETERMAN ED, Te Brake LHM, de Knegt GJ, van der Meijden A, et al
   Assessment of the additional value of verapamil to a moxifloxacin and linezolid combination regimen in a murine tuberculosis model.
   Antimicrob Agents Chemother. 2018 Jul 9. pii: AAC.01354.
   PubMed     Text format     Abstract available
   
   

   
   Clin Infect Dis

4. HOUBEN RMGJ, Lalli M, Kranzer K, Menzies NA, et al
   What if they don't have tuberculosis? The consequences and trade-offs involved in false-positive diagnoses of tuberculosis.
   Clin Infect Dis. 2018 Jul 5. pii: 5049169. doi: 10.1093.
   PubMed     Text format     Abstract available
   
   

   
   Int J Tuberc Lung Dis

5. CHAWLA K, Kumar A, Shenoy VP, Chauhan DS, et al
   Strain diversity and relative transmission of Mycobacterium tuberculosis in south coastal Karnataka, India.
   Int J Tuberc Lung Dis. 2018;22:878-883.
   PubMed     Text format     Abstract available
   
   
6. CHAUDHARY A, Singh JP, Sehajpal PK, Sarin BC, et al
   P2X7 receptor polymorphisms and susceptibility to tuberculosis in a North Indian Punjabi population.
   Int J Tuberc Lung Dis. 2018;22:884-889.
   PubMed     Text format     Abstract available
   
   
7. COLLINS D, Beyene D, Tedla Y, Mesfin H, et al
   Can patients afford the cost of treatment for multidrug-resistant tuberculosis in Ethiopia?
   Int J Tuberc Lung Dis. 2018;22:905-911.
   PubMed     Text format     Abstract available
   
   
8. NAM VX, Nhung NV, Hoa NB, Thuy HTT, et al
   Economic burden of multidrug-resistant tuberculosis: a multicenter study across Vietnamese regions.
   Int J Tuberc Lung Dis. 2018;22:912-917.
   PubMed     Text format     Abstract available
   
   
9. TURNER RD, Birring SS, Darmalingam M, Hooper RL, et al
   Daily cough frequency in tuberculosis and association with household infection.
   Int J Tuberc Lung Dis. 2018;22:863-870.
   PubMed     Text format     Abstract available
   
   
10. VAN DER HEIJDEN YF, Karim F, Chinappa T, Mufamadi G, et al
    Older age at first tuberculosis diagnosis is associated with tuberculosis recurrence in HIV-negative persons.
    Int J Tuberc Lung Dis. 2018;22:871-877.
    PubMed     Text format     Abstract available
    
    
11. DUNBAR R, Naidoo P, Beyers N, Langley I, et al
    Improving rifampicin-resistant tuberculosis diagnosis using Xpert((R)) MTB/RIF: modelling interventions and costs.
    Int J Tuberc Lung Dis. 2018;22:890-898.
    PubMed     Text format     Abstract available
    
    
12. HIRSCH-MOVERMAN Y, Mantell JE, Lebelo L, Wynn C, et al
    Tuberculosis preventive treatment preferences among care givers of children in Lesotho: a pilot study.
    Int J Tuberc Lung Dis. 2018;22:858-862.
    PubMed     Text format     Abstract available
    
    
13. MALIK AA, Amanullah F, Codlin AJ, Siddiqui S, et al
    Improving childhood tuberculosis detection and treatment through facility-based screening in rural Pakistan.
    Int J Tuberc Lung Dis. 2018;22:851-857.
    PubMed     Text format     Abstract available
    
    
14. SHETE PB, Boccia D, Dhavan P, Gebreselassie N, et al
    Defining a migrant-inclusive tuberculosis research agenda to end TB.
    Int J Tuberc Lung Dis. 2018;22:835-843.
    PubMed     Text format     Abstract available
    
    
15. DOOLEY KE
    Long-acting injectables for tuberculosis prophylaxis and treatment: is now the time?
    Int J Tuberc Lung Dis. 2018;22:833-834.
    PubMed     Text format    
    
    
16. CAMINERO JA, Scardigli A
    The economic burden of multidrug-resistant tuberculosis.
    Int J Tuberc Lung Dis. 2018;22:831-832.
    PubMed     Text format    
    
    
17. SCHNIPPEL K, Firnhaber C, Page-Shipp L, Sinanovic E, et al
    Impact of adverse drug reactions on the incremental cost-effectiveness of bedaquiline for drug-resistant tuberculosis.
    Int J Tuberc Lung Dis. 2018;22:918-925.
    PubMed     Text format     Abstract available
    
    
18. COURT RG, Wiesner L, Chirehwa MT, Stewart A, et al
    Effect of lidocaine on kanamycin injection-site pain in patients with multidrug-resistant tuberculosis.
    Int J Tuberc Lung Dis. 2018;22:926-930.
    PubMed     Text format     Abstract available
    
    
19. CHAN ED
    Thin body habitus is a risk factor for active pulmonary tuberculosis, but not for infection.
    Int J Tuberc Lung Dis. 2018;22:967-968.
    PubMed     Text format    
    
    
20. ZELLWEGER JP
    Multidrug-resistant tuberculosis in Ukraine: what is hidden behind the numbers?
    Int J Tuberc Lung Dis. 2018;22:966-967.
    PubMed     Text format    
    
    
21. YAN ZH, Yi L, Wei PJ, Jia HY, et al
    Evaluation of panels of Mycobacterium tuberculosis antigens for serodiagnosis of tuberculosis.
    Int J Tuberc Lung Dis. 2018;22:959-965.
    PubMed     Text format     Abstract available
    
    
22. DUPNIK KM, Bean JM, Lee MH, Jean Juste MA, et al
    Blood transcriptomic markers of Mycobacterium tuberculosis load in sputum.
    Int J Tuberc Lung Dis. 2018;22:950-958.
    PubMed     Text format     Abstract available
    
    
23. RAJOLI RKR, Podany AT, Moss DM, Swindells S, et al
    Modelling the long-acting administration of anti-tuberculosis agents using PBPK: a proof of concept study.
    Int J Tuberc Lung Dis. 2018;22:937-944.
    PubMed     Text format     Abstract available
    
    
24. ZHU H, Guo SC, Liu ZQ, Wang B, et al
    Therapeutic drug monitoring of cycloserine and linezolid during anti-tuberculosis treatment in Beijing, China.
    Int J Tuberc Lung Dis. 2018;22:931-936.
    PubMed     Text format     Abstract available
    
    
25. SOMOSKOVI A, Gutierrez C
    Gaps in understanding factors influencing tuberculosis recurrence.
    Int J Tuberc Lung Dis. 2018;22:830.
    PubMed     Text format    
    
    

    
    J Antimicrob Chemother

26. WHITFIELD MG, Warren RM, Mathys V, Scott L, et al
    The potential use of rifabutin for treatment of patients diagnosed with rifampicin-resistant tuberculosis.
    J Antimicrob Chemother. 2018 Jul 5. pii: 5049577. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    

    
    J Clin Microbiol

27. WALTERS E, Scott L, Nabeta P, Demers AM, et al
    Molecular detection of Mycobacterium tuberculosis from stool in young children using a novel centrifugation-free processing method.
    J Clin Microbiol. 2018 Jul 11. pii: JCM.00781-18. doi: 10.1128/JCM.00781.
    PubMed     Text format     Abstract available
    
    
28. DE VOS M, Derendinger B, Dolby T, Simpson J, et al
    Diagnostic accuracy and utility of a new molecular assay for multidrug-resistant tuberculosis: FluoroType MTBDR.
    J Clin Microbiol. 2018 Jul 5. pii: JCM.00531-18. doi: 10.1128/JCM.00531.
    PubMed     Text format     Abstract available
    
    

    
    J Infect Dis

29. GEBREMICAEL G, Kassa D, Quinten E, Alemayehu Y, et al
    Host gene expression kinetics during treatment of tuberculosis in HIV-coinfected individuals is independent of HAART therapy.
    J Infect Dis. 2018 Jul 2. pii: 5047436. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    

    
    Lancet Infect Dis

30. TRAUER JM, Ragonnet R, McBryde ES
    Appropriate comparisons of tuberculosis latency structures with empiric data.
    Lancet Infect Dis. 2018;18:720-721.
    PubMed     Text format    
    
    
31. BURKI T
    Neglecting childhood tuberculosis "a human rights violation".
    Lancet Infect Dis. 2018;18:723.
    PubMed     Text format    
    
    

    
    Lancet Respir Med

32. SCHNIPPEL K, Ndjeka N, Maartens G, Meintjes G, et al
    Effect of bedaquiline on mortality in South African patients with drug-resistant tuberculosis: a retrospective cohort study.
    Lancet Respir Med. 2018 Jul 9. pii: S2213-2600(18)30235.
    PubMed     Text format     Abstract available
    
    
33. RIVA MA, Belingheri M, Cesana G
    Pulmonary tuberculosis in Pope Clement XI.
    Lancet Respir Med. 2018;6:497-498.
    PubMed     Text format    
    
    
34. GUPTA R, Wells CD
    Pan-tuberculosis regimens: re-framing the argument.
    Lancet Respir Med. 2018;6:e28.
    PubMed     Text format    
    
    
35. MITTAL S, Tiwari P, Madan K, Khilnani GC, et al
    Isoniazid-resistant, rifampicin-susceptible tuberculosis in India.
    Lancet Respir Med. 2018;6:e29.
    PubMed     Text format    
    
    

    
    N Engl J Med

36. NEMES E, Geldenhuys H, Rozot V, Rutkowski KT, et al
    Prevention of M. tuberculosis Infection with H4:IC31 Vaccine or BCG Revaccination.
    N Engl J Med. 2018;379:138-149.
    PubMed     Text format     Abstract available
    
    

    
    PLoS Med

37. HARAUSZ EP, Garcia-Prats AJ, Law S, Schaaf HS, et al
    Treatment and outcomes in children with multidrug-resistant tuberculosis: A systematic review and individual patient data meta-analysis.
    PLoS Med. 2018;15:e1002591.
    PubMed     Text format     Abstract available
    
    

    
    PLoS One

38. VELAYUTHAM B, Chadha VK, Singla N, Narang P, et al
    Recurrence of tuberculosis among newly diagnosed sputum positive pulmonary tuberculosis patients treated under the Revised National Tuberculosis Control Programme, India: A multi-centric prospective study.
    PLoS One. 2018;13:e0200150.
    PubMed     Text format     Abstract available
    
    
39. WILLEMSE D, Weber B, Masino L, Warren RM, et al
    Rv1460, a SufR homologue, is a repressor of the suf operon in Mycobacterium tuberculosis.
    PLoS One. 2018;13:e0200145.
    PubMed     Text format     Abstract available
    
    
40. SILVA DAAD, Silva MVD, Barros CCO, Alexandre PBD, et al
    TNF-alpha blockade impairs in vitro tuberculous granuloma formation and down modulate Th1, Th17 and Treg cytokines.
    PLoS One. 2018;13:e0194430.
    PubMed     Text format     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Tuberculosis is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: